Regenera eyes deal worth up to $130m
08 April, 2005 by Renate KrelleRegenera (ASX:RGA) has signed deal with an affiliate of US opthamology giant Alcon, which one independent source has valued at US$100 million (AUD$130 million), for a steroid technology it licensed in only last year which is used in eye surgery.
A productive dose of medicines
08 April, 2005 by Kieran Schneemann and Brendan ShawThe pressure of healthcare costs in the future will bring better health outcomes, predict Kieran Schneemann and Brendan Shaw.
Peptech has high hopes for new antibody
07 April, 2005 by Graeme O'NeillSydney peptide therapeutics developer Peptech (ASX:PTD) has taken delivery of its hot new anti-inflammatory domain antibody (dAb) from UK ally Domantis, and plans to begin human clinical trials in 2007.
GSK award winner at forefront of quest for new kidney treatment
07 April, 2005 by Graeme O'NeillStart small, but think big, could be Melissa Little's motto. The kidney disease researcher, an associate professor at the University of Queensland's Institute of Molecular Bioscience, is hunting molecules that may stimulate failing kidneys to repair themselves -- but her ultimate goal is to be able to program stem cells to grow new kidneys from scratch.
ISPE aims to build bridges to biotech
07 April, 2005 by Iain ScottAn international conference to be held in Australia next week has particular relevance for the future of Australia's biotech and pharmaceutical industries, writes Iain Scott.
ES cells showing promise in tissue therapy
07 April, 2005 by Susan WilliamsonA new technique that involves seeding 3D biodegradable polymer scaffolds with human embryonic stem (hES) cells is showing promise as a way to create human tissues for therapeutic applications, an Israeli researcher has told a workshop in Sydney.
QBF puts $2.5m to Xenome drug development
06 April, 2005 by Graeme O'NeillUnlisted Brisbane biotech Xenome has secured $2.5 million in new funding from its major shareholder, the Queensland Biocapital Fund (QBF), to accelerate development of its product pipeline, including its pain-killing peptide from cone-shell toxin, Xen2174.
Chemeq banks $40m
05 April, 2005 by Staff WritersBeleaguered biotech Chemeq (ASX:CMQ) has seen some light on the horizon, announcing it has successfully banked AUD$40 million from an issue of 40,000 convertible bonds to Japanese investment group Mizuho International and related entities of investment management group Stark Investments.
The role of commercialisation in biotechnology
05 April, 2005 by Rowan GilmoreCollaboration and cooperation are key when taking research to market, writes Rowan Gilmore.
US biotech pendulum swings towards M&A
05 April, 2005 by Renate KrelleAlthough US biotechs managed to raise a healthy US$6.2 billion in capital in the first quarter of 2005, the tide has turned against IPOs, and mergers and acquisitions and partnering are gaining popularity as alternative financing methods, according to analysis by San Francisco's Burrill & Company.
Medsaic wins NSW biotech commercialisation award
05 April, 2005 by Iain ScottDiagnostic platform developer Medsaic has won the NSW government's inaugural BioFirst commercialisation award, at a ceremony on Monday evening.
HatchTech aims to scratch an itch in head lice market
05 April, 2005 by Graeme O'NeillFeeling lousy? Unlisted Melbourne biotech HatchTech believes it may have just the remedy: a safe, potent ovicide that kills the eggs of the common head louse.
UK legislators demand pharma shake-up
05 April, 2005 by Staff WritersA tougher regulatory regime, curbs on drug promotion, financial penalties for companies that break advertising rules, and a register of industry gifts to healthcare professionals have been demanded by British legislators.
The pharmaceutical forecast
05 April, 2005 by Ian NisbetA new environment for pharmaceutical companies is on the horizon and it will be the fittest who survive, predicts Ian Nisbet.
Port Phillip Bay dolphin identified as unique species
04 April, 2005 by Graeme O'NeillMelburnians appear to have been living with an unrecognised new species of dolphin, unique to Port Phillip Bay.
